Hi, we've made some changes

GlaxoSmithKline(GSK)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE 100

Market Cap

£61,934m

Change Today

Price Down-7.50p

Share Price

1,173.50p

GlaxoSmithKline Overview

UK-based GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000. It employ’s over 100,000 people worldwide and has 99 manufacturing sites in 39 countries dotted round the world.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Income & Efficiency

Latest F'cast
Div Yield 4.5% 5.0%
Div Cover 1.9 1.8
Op Mrgn 33.4% 30.6%
ROCE 46.1%  

Valuation

Latest F'cast
P/E 11.8 12.1
PEG n/a n/a
Pr/Revenue 2.7 2.7
Pr/Book 6.2  

Growth

Latest F'cast
Revenue n/a 1.4%
PBT n/a -5.4%
EPS n/a -1.7%
DPS n/a 3.0%

GlaxoSmithKline Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-03 a21,441.00 a6,313.00 82.00p 15.6 3.1 +5% 41.00p 3.2%
31-Dec-04 a19,986.00 a5,779.00 68.10p 17.9 n/a -17% 42.00p 3.4%
31-Dec-05 23,225.00 7,799.00 95.50p 15.4 0.4 +40% 48.00p 3.3%
31-Dec-06 22,716.00 7,452.00 99.10p 13.6 3.4 +4% 53.00p 3.9%
31-Dec-07 22,716.00 7,452.00 99.10p 12.9 n/a n/a 53.00p 4.1%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GlaxoSmithKline Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-08 23,026.51 7,049.55 97.41p 12.0 n/a -2% 54.60p 5.0%
31-Dec-09 23,355.22 7,356.32 104.05p 11.3 1.7 +7% 58.13p 5.3%

Covering analysts: ABN AMRO, Argus Research, Aurel, Bayerische Landesbank, BBVA, Bernstein Research, CA Cheuvreux, Charles Stanley & Co, Citigroup Investment Research, Collins Stewart, Credit Suisse, Deutsche Bank Research, DZ Bank, ESN-NCB Stockbrokers, Goldman Sachs, Helvea SA, HSBC Securities, IIR Group, ING Wholesale Banking, JP Morgan, Landesbank Baden-Württemberg, Lehman Bros, Merrill Lynch, Morgan Stanley, Natixis Securities, Oddo Securities, Panmure Gordon, Raymond James Euro Equities, Société Générale, Standard & Poors, UBS, WestLB Equity Markets

GlaxoSmithKline Company Announcements

Transaction in Own Shares 04-Jul-2008 17:02 RNS
Transaction in Own Shares 03-Jul-2008 17:11 RNS
Transaction in Own Shares 02-Jul-2008 17:05 RNS

GlaxoSmithKline ShareCast News

Sector movers: Drugs groups still buzzing 03-Jul-2008 ShareCast
London close: Miners drag Footsie under 02-Jul-2008 ShareCast
Sector movers: Pharmas on a high after Astra vic... 02-Jul-2008 ShareCast

GlaxoSmithKline Top Newspaper Links

Local Briefing 02-Jul-2008 Washington Post
Iraq lodges $10bn lawsuit over ‘Oil-for-Food scam’ 02-Jul-2008 Times
Iraq oil-for-food lawsuit names drug giants 02-Jul-2008 Telegraph

Latest GlaxoSmithKline Director Deals

Traded Action Notifier PriceAmountValue
30-Jun-08 Transfer From Dr Dan Podolsky 0.000p 1,409 £0.00
30-Jun-08 Transfer From Sir Robert Wilson 0.000p 643 £0.00
30-Jun-08 Transfer From Tom De Swaan 0.000p 699 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GlaxoSmithKline Market Data

Currency UK Pounds
Share Price 1,173.50p Price Down
Change Today -7.50p
52 Week High 1,385.00p
52 Week Low 1,001.00p
Volume 11,368,615
Shares Issued 5,278m
Market Cap £61,934m
Beta 0.56
RiskGrade 116

GlaxoSmithKline Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
61.96% below the market average61.96% below the market average61.96% below the market average61.96% below the market average61.96% below the market average
87.95% above the sector average87.95% above the sector average87.95% above the sector average87.95% above the sector average87.95% above the sector average
Price Trend
23.11% above the market average23.11% above the market average23.11% above the market average23.11% above the market average23.11% above the market average
51.65% above the sector average51.65% above the sector average51.65% above the sector average51.65% above the sector average51.65% above the sector average
Income
32.76% above the market average32.76% above the market average32.76% above the market average32.76% above the market average32.76% above the market average
81.82% above the sector average81.82% above the sector average81.82% above the sector average81.82% above the sector average81.82% above the sector average
Growth
64.59% below the market average64.59% below the market average64.59% below the market average64.59% below the market average64.59% below the market average
76% below the sector average76% below the sector average76% below the sector average76% below the sector average76% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 16
Sell 5
Strong Sell 3
Total 31
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GlaxoSmithKline Dividends

  Latest Previous
  Q1 Q4
Ex-Div 30-Apr-08 13-Feb-08
Paid 10-Jul-08 10-Apr-08
Amount 13.00p 16.00p

Trades for 04-Jul-2008

Time Volume / Share Price
17:06 18,000 @ 1,172.91p
16:49 30,000 @ 1,180.75p
16:35 1,077,497 @ 1,173.50p
16:31 7,400 @ 1,171.99p
16:29 2 @ 1,175.00p

GlaxoSmithKline Key Personnel

CEO Jean-Pierre Garnier
CFO Julian Heslop
Chair Moncef Slaoui

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).